Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Products are for professional/laboratory use only.
Biocartis is pleased to announce the publication of an important study [1] by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.